Rocket One Inc.
Hoth Therapeutics, Inc. (Nasdaq: HOTH) is a clinical-stage biopharmaceutical company focused on developing novel therapies for unmet medical needs across multiple therapeutic areas. The company operates without a website URL disclosed in the filing and maintains its principal executive offices in New Jersey. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Rocket One Inc. does
In the company’s own words
Hoth Therapeutics, Inc. (Nasdaq: HOTH) is a clinical-stage biopharmaceutical company focused on developing novel therapies for unmet medical needs across multiple therapeutic areas. The company operates without a website URL disclosed in the filing and maintains its principal executive offices in New Jersey.
The company's primary development pipeline includes several product candidates at various stages of advancement. HT-001 is a topical formulation under development for treating dermatological side effects from epidermal growth factor receptor inhibitors used in cancer therapy. The company received FDA approval in December 2022 to proceed with Phase 2a clinical trials and expanded to European trials in January 2026. HT-KIT targets mast cell-derived cancers and anaphylaxis through selective inhibition of the KIT receptor tyrosine kinase, with orphan drug designation granted in March 2022. HT-ALZ, for which the company received a patent in November 2024, is being developed to treat and prevent Alzheimer's disease and other neuroinflammatory diseases using the Section 505(b)(2) regulatory pathway.
Additional assets in development include the BioLexa Platform, an exclusive license from the University of Cincinnati for treating atopic dermatitis through a combination of zinc chelators and approved antibiotics; HT-004, an exon-skipping oligonucleotide therapy for asthma and allergies; and HT-VA, a glial cell line derived neurotrophic factor licensed from the Department of Veterans Affairs for treating obesity and related metabolic conditions.
Hoth operates as a clinical-stage company without manufacturing capabilities, relying on contract manufacturing organizations and third-party collaborators for development and potential commercialization. The company has established intellectual property portfolios including licenses to multiple U.S. patents and pending applications across international jurisdictions. The company maintains sponsored research agreements with academic institutions including North Carolina State University, Washington University in St. Louis, and the University of Cincinnati to advance its preclinical and clinical development programs.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- HOBOKEN, NJ
- Fiscal year end
- December
- CIK
- 1711786
- SIC
- 2834
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Rocket One Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Rocket One Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Rocket One Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Rocket One Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Rocket One Inc.'s last four quarterly filings that the numbers alone won't show?”